文献速递贫血与红细胞疾病

在撒哈拉以南非洲镰状细胞贫血患儿中应用羟基脲减少输血需求:I/II期REACH试验分析

Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial.
PubMed 文献 · Am J Hematol · 2024-02-08

REACH为在安哥拉、刚果民主共和国、肯尼亚和乌干达开展的羟基脲治疗镰状细胞贫血(SCA)患儿的纵向I/II期试验。635例患儿(4124人年观察)中258例(40.4%)共接受545次输血;最大耐受剂量(MTD)阶段输血发生率较治疗前降低75%(IRR 0.25,95%CI 0.18-0.35,p<.0001),较固定剂量阶段降低50%(IRR 0.50,95%CI 0.39-0.63,p<.0001)。

要点

  • 每100人年输血率:治疗前43.2、固定剂量21.7、剂量递增14.5、MTD 10.8。
  • MTD阶段输血发生率较治疗前降低75%(IRR 0.25,95%CI 0.18-0.35,p<.0001)。
  • MTD阶段输血发生率较固定剂量阶段降低50%(IRR 0.50,95%CI 0.39-0.63,p<.0001)。

核心结论

  • MTD羟基脲可降低非洲SCA患儿的输血利用;若广泛实施,普及检测并在MTD治疗或可预防撒哈拉以南非洲全部儿科输血中的21%。
  • 增加SCA患儿羟基脲可及性应能减轻输血负担并增加整体血液供应。

研究设计与样本

  • REACH(Realizing Effectiveness Across Continents with Hydroxyurea,NCT01966731)为在安哥拉、刚果民主共和国、肯尼亚和乌干达开展的羟基脲治疗SCA患儿的纵向I/II期试验。
  • 入组后先有2个月治疗前筛查期,随后6个月固定剂量羟基脲(15-20 mg/kg/天)、18个月剂量递增,之后以MTD稳定给药。
  • 共纳入635例患儿,观察4124人年;采用单因素和多因素模型分析输血相关特征,并计算各治疗阶段的输血发生率比(IRR)。

主要发现

  • 258例参与者(40.4%)共接受545次输血。
  • 每100人年输血率:治疗前43.2、固定剂量阶段21.7、剂量递增阶段14.5、MTD阶段10.8。
  • MTD阶段输血发生率较治疗前降低75%(IRR 0.25,95%CI 0.18-0.35,p<.0001),较固定剂量阶段降低50%(IRR 0.50,95%CI 0.39-0.63,p<.0001)。

临床怎么用

  • 作者认为,若广泛实施,普及检测并在MTD给予羟基脲或可预防撒哈拉以南非洲全部儿科输血中的21%。
  • 作者认为,增加SCA患儿羟基脲可及性应能减轻输血负担并增加整体血液供应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Children with sickle cell anemia (SCA) in Africa frequently require transfusions for SCA complications. Despite limited blood supplies, strategies to reduce their transfusion needs have not been widely evaluated or implemented. We analyzed transfusion utilization in children with SCA before and during hydroxyurea treatment. REACH (Realizing Effectiveness Across Continents with Hydroxyurea, NCT01966731) is a longitudinal Phase I/II trial of hydroxyurea in children with SCA from Angola, Democratic Republic of Congo, Kenya, and Uganda. After enrollment, children had a two-month pre-treatment screening period followed by 6 months of fixed-dose hydroxyurea (15-20 mg/kg/day), 18 months of dose escalation, and then stable dosing at maximum tolerated dose (MTD). Characteristics associated with transfusions were analyzed with univariate and multivariable models. Transfusion incidence rate ratios (IRR) across treatment periods were calculated. Among 635 enrolled children with 4124 person-years of observation, 258 participants (40.4%) received 545 transfusions. The transfusion rate per 100 person-years was 43.2 before hydroxyurea, 21.7 on fixed-dose, 14.5 during dose escalation, and 10.8 on MTD. During MTD, transfusion incidence was reduced by 75% compared to pre-treatment (IRR 0.25, 95% confidence interval [CI] 0.18-0.35, p < .0001), and by 50% compared to fixed dose (IRR 0.50, 95% CI 0.39-0.63, p < .0001). Hydroxyurea at MTD decreases transfusion utilization in African children with SCA. If widely implemented, universal testing and hydroxyurea treatment at MTD could potentially prevent 21% of all pediatric transfusions administered in sub-Saharan Africa. Increasing hydroxyurea access for SCA should decrease the transfusion burden and increase the overall blood supply.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Power-Hays A, Tomlinson GA, Tshilolo L, et al. Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial. Am J Hematol. 2024. PMID: 38332651. doi:10.1002/ajh.27244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。